ProMIS Neurosciences is trading 6.49% down at $12.10, with the decline appearing primarily tied to broad risk-off trading as Treasury yields and crude oil rise.
- No new company-specific announcement was identified for September 24, 2026.
- Recent company coverage remains focused on September conferences and previously reported PMN310 Alzheimer’s trial data.
- Biotechnology is down 2.04%, pressuring growth-oriented healthcare stocks.